Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 14, 2026, NDA 19937 (Adenocard), held by Astellas, was first approved by FDA on Oct 30, 1989, with 21 approved supplements and 0 published complete response letters.
First approved: Oct 30, 1989
Review: Priority
Supplements approved: 21
Complete response letters: 0
Approvals and New Uses
The original application and every efficacy supplement, newest first; all 22 submissions below
Date
Submission
Status
Documents
Oct 30, 1989
Original applicationNew molecular entity · Priority review
Approved
None posted
Products
1 strengths and forms
Product
Active ingredient
Marketing
Adenocard3MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · injectable;injection
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
